Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ArtPlac

Financiado

Cerrado

Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support...

Artificial Placenta (ArtPlac) - Miniaturized Integrated Lung and Kidney Support for Critically Ill Newborns This Pathfinder project will establish a radical change in the treatment of newborns using an artificial placenta (ArtPlac). What drives us towards a radical new treatment approach? 2 mio. neonatal deaths that occur worldwide year... ver más

31/03/2027

KLINIKUM NURNBERG

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

KLINIKUM NURNBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-01-19

HORIZON-EIC-2022-PATHFINDEROPEN-01-01: EIC Pathfinder Open 2022 Scope:You should apply to this call if you are looking for support from EIC Pathfinder Open to reali...

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

KLINIKUM NURNBERG

928.68K€ | Lider

MCMASTER UNIVERSITY

KTH

203.75K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PLS Perinatal Life Support System Integration of Enabling Techn... 3M€ Cerrado

OXYPREM Precise brain oxygen monitoring for high risk preterm infant... 71K€ Cerrado

FGR PODS Fetal Growth Restriction Perinatal Outcome Decision Support... 2M€ Cerrado

CRADL Continuous Regional Analysis Device for neonate Lung 6M€ Cerrado

Pregnolia A simple reliable and safe diagnostic device for preterm bi... 71K€ Cerrado

MIRACLE DISPOSITIVO MÉDICO PARA EL DIAGNÓST... MIRACLE DISPOSITIVO MÉDICO PARA EL DIAGNÓSTICO DE ENFERMED... 503K€ Cerrado

Duración del proyecto: 50 meses Fecha Inicio: 2023-01-19
Fecha Fin: 2027-03-31

Líder del proyecto

KLINIKUM NURNBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This Pathfinder project will establish a radical change in the treatment of newborns using an artificial placenta (ArtPlac). What drives us towards a radical new treatment approach? 2 mio. neonatal deaths that occur worldwide yearly. The technological advancements of the last fifty years were based on scaling down adult devices which are not ideal for all babies. Why? Because babies are not just small adults! In fact, the applied treatments are very invasive and cause side effects by damaging their sensitive bodies. Survivors often suffer from life-long complications or cannot live independently. In utero, the placenta is a life-giving organ and serves as fetal lung, fetal kidney, and feeder. Because the placenta cannot be reconnected after preterm birth, we aim to continue the placental support with ArtPlac. Our novel device simply connects to the belly button for lung and kidney support while the newborn can breathe, mature, and heal. To achieve this, a novel compact and miniaturized all-in-one artificial placenta device combining lung and kidney functions will be developed. Our plug-in approach will use the natural umbilical vessels at the belly button with expandable catheters to provide a large bore vascular access like in utero. This allows ArtPlac to be driven solely by the newborn's heart like in the womb. Inline sensors will analyze blood parameters without painful collection. Feedback loops in ArtPlac will provide individual demand-driven support. Inbuilt features for hemocompatibility will prevent thrombosis and use of high-dose systemic anticoagulation with the high risk for brain bleeding. Importantly, ArtPlac allows family integrated care providing a therapy for the newborn in close connection to its family. In summary, our visionary approach revolutionizes the treatment of newborns after birth. It will reduce brain damage and comorbidities, promote long-term health, and therefore improve the survival chances of up to 1.2 mio. newborns per year.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores